单位:[1]Department of Gynecology and Obstetrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030 Hubei,PR China华中科技大学同济医学院附属同济医院妇产科学系普通妇科[2]Cancer Genetics Laboratory of Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia[3]Department of Gynecology Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071 Hubei, PR China[4]Department of Gynecology and Obstetrics, The Central Hospital of Wuhan, Wuhan 430030 Hubei, PR China[5]Department of Gastrointestinal Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030 Hubei,PR China华中科技大学同济医学院附属同济医院外科学系胃肠外科[6]Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Ovarian cancer selective metastasizes to the omentum contributing to the poor prognosis associated with ovarian cancer. However, the mechanism underlining this propensity and therapeutic approaches to counter this process has not been fully elucidated. Here, we show that MCP-1 produced by omental adipocytes binding to its cognate receptor CCR-2 on ovarian cancer cells facilitates migration and omental metastasis by activating the PI3K/AKT/mTOR pathway and its downstream effectors HIF-1 alpha and VEGF-A in cell lines, xenografts, and transgenic murine models. MCP-1 antibody significantly decreased tumor burden and increased survival of mice in vivo. Interestingly, metformin decreased omental metastasis at least partially by inhibiting MCP-1 secretion from adipocytes independent of direct effects on cancer cells. Together this suggests a novel target of MCP-1/CCR-2 axis that could benefit ovarian cancer patients.
基金:
National Key R&D Program of China [2016YFC1303100]; National Basic Research Program of China (973 Program)National Basic Research Program of China [2015CB553903]; Nature and Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81272859, 81572569, 81402163, 81402164, 81501530, 81671394, 81370469]; International S&T Cooperation Program of China [2013DFA31400]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50CA217685]; Ovarian Cancer Research Foundation
第一作者单位:[1]Department of Gynecology and Obstetrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030 Hubei,PR China
通讯作者:
推荐引用方式(GB/T 7714):
sun chaoyang,li xi,guo ensong,et al.MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis[J].ONCOGENE.2020,39(8):1681-1695.doi:10.1038/s41388-019-1090-1.
APA:
sun,chaoyang,li,xi,guo,ensong,li,na,zhou,bo...&chen,gang.(2020).MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.ONCOGENE,39,(8)
MLA:
sun,chaoyang,et al."MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis".ONCOGENE 39..8(2020):1681-1695